Table 2 Response rates based on Intent-to-Treat population (n = 45) and in patients who have completed at least two cycles of the experimental combination (n = 42)
Characteristics | Intent-to-Treat patients No (%) | Patients completing at least two cycles of treatment No (%) |
|---|---|---|
Patients | 45 | 42 |
Clinical response | Â | Â |
   Complete | 3 (6.7) | 3 (7.1) |
   Partial | 10 (22.2) | 10 (23.8) |
   Stable disease | 13 (28.9) | 12 (28.6) |
   Progression | 19 (42.2) | 17 (40.5) |
Duration of response, months Median (range) | 6 (3-13) | 6 (3-13) |
Duration of stabilization, months Median (range) | 5 (3-10) | 5 (3-10) |
Serological Response* | Â | Â |
   Complete | 8 (19.0) | 8 (20.5) |
   Partial | 9 (21.4) | 8 (20.5) |
   Stabilization | 12 (28.6) | 11 (28.2) |
   Progression | 13 (31.0) | 12 (30.8) |